Laboratory Corporation of America Holdings (LabCorp) Announces the Availability of Expanded Services for Inflammatory Bowel Disease

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the availability of an expanded testing menu to help clinicians diagnose, treat and monitor the course of Inflammatory Bowel Disease (IBD). Gastrointestinal (GI) tract disorders are often presented with non-specific symptoms and are difficult to diagnose, especially in primary care settings. Inflammatory Bowel Disease (IBD) is one of the most common and serious gastrointestinal disorders. The two clinically distinctive forms of IBD are ulcerative colitis and Crohn's disease. Treatments can also be complicated, involving immunosuppressant therapies, biological drugs and/or surgery.